Mazdutide
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects
Innovent · Phase 1/2 · Completed · Enrollment 60
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| IBI362 | n/r | n/r | n/r | n/r |
| placebo | n/r | n/r | n/r | n/r |
Not shown
- IBI362: endpoint not reported
- placebo: endpoint not reported